DESTINY-Breast03 trial results ‘practice-changing’

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Springer Healthcare

DESTINY-Breast03 trial results ‘practice-changing’

Oncology Breast Cancer ESMO-2021

Description

Barbara Pistilli discusses the “practice-changing” findings from the DESTINY-Breast03 trial for HER2-positive metastatic breast cancer

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.